Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.77 |
| ▸ | GFER | P55789 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SMO | Q99835 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494756 | 0.91 | RAB9A (0.79) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL1494886 | 0.91 | KDM4E (0.64) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL4727616 | 0.85 | KDM4E (0.82) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL1494832 | 0.81 | KDM4E (0.83) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL6389098 | 0.81 | KDM4E (0.72) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL4726403 | 0.81 | KDM4E (0.76) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL25878632 | 0.81 | KDM4E (0.74) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL980106 | 0.80 | RAB9A (0.78) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL25312016 | 0.80 | ALDH1A1 (0.81) | KDM4ESMN1; SMN2LMNARAB9APOLB | |
| SCHEMBL29484580 | 0.80 | ALDH1A1 (0.81) | KDM4ESMN1; SMN2LMNARAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2008029152-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | KDM4E 2241/4885SMN1; SMN2 1838/4885LMNA 2569/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | KDM4E 1406/4885SMN1; SMN2 981/4885LMNA 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.